Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.
At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.
In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Cancer Tumor Profiling Market Size, Share & Growth 2025-2030
Cancer Tumor Profiling Market Size, Share & Growth 2025-2030
Cancer Tumor Profiling Market
Cancer Tumor Profiling Market Size, Share & Growth 2025-2030
Cancer Tumor Profiling Market by Technology (NGS, IHC, PCR, Microarrays, FISH, Others), by Technique (Genomics, Proteomics, Epigenetics, Others), by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others), by Application (Personalized Cancer Medicine, Research, Clinical, Screening, Diagnostics, Prognostics, Others), by Process Type (Genomics, Others), by North America (USA, Canada, Mexico), by Europe (Germany, UK, France, Italy, Spain, Rest of Europe), by Asia Pacific (China, Japan, India, South Korea, Australia, Rest of APAC), by Latin America (Brazil, Argentina, Rest of LATAM), by Middle East & Africa (South Africa, Saudi Arabia, Rest of MEA) Forecast 2026-2034
Updated On : Nov 4, 2026|Base Year : 2025|Pages : 190
The global cancer tumor profiling market is entering a rapid expansion phase. Our proprietary primary research and direct expert interviews value the market at approximately USD 14.5 billion in 2026, projected to reach USD 21.7 billion by 2030, reflecting a CAGR of 10.4% over the forecast window. The proliferation of comprehensive genomic profiling, the shift toward precision oncology, and the emergence of liquid biopsy platforms are fundamentally reshaping the clinical pathway for cancer diagnosis and treatment selection.
Cancer Tumor Profiling Market Size (In Billion)
25.0B
20.0B
15.0B
10.0B
5.0B
0
13.13 B
2025
14.50 B
2026
16.01 B
2027
17.67 B
2028
19.51 B
2029
21.54 B
2030
23.78 B
2031
Cancer Tumor Profiling Market Size (In Billion)
Year
Market Size
2025
13.13 B
2026
14.50 B
2027
16.01 B
2028
17.67 B
2029
19.51 B
2030
21.54 B
2031
23.78 B
Key structural drivers include an aging global population, rising cancer incidence, and the expanding role of tumor profiling across the entire patient journey. According to benchmarks from the World Health Organization (WHO), approximately 20 million new cancer cases and 9.7 million cancer deaths were recorded in 2022 alone. This enormous disease burden, coupled with the growing availability of targeted therapies requiring companion diagnostics, is accelerating adoption across both academic and community oncology settings.
Market Drivers & Restraints
The demand for tumor profiling is underpinned by several convergent forces.
Precision oncology adoption: Clinicians are increasingly ordering comprehensive panels to match patients with targeted therapies and immunotherapies, improving outcomes and minimizing adverse events.
Technological advancement: Next-generation sequencing (NGS) enables rapid, cost-effective analysis of hundreds of genes, including fusions, copy number alterations, and biomarkers such as MSI and TMB.
Liquid biopsy expansion: Non-invasive testing is opening access for patients with insufficient tissue samples and enabling longitudinal monitoring.
Reimbursement improvements: Medicare and private payer coverage for profiling tests is expanding, reducing financial barriers.
However, the market faces notable constraints.
High costs and variable reimbursement: Out-of-pocket expenses and inconsistent coverage across geographies limit uptake, particularly in community hospitals and developing nations.
Sample quality and insufficiency: Many tissue samples are inadequate for large panels, leading to inconclusive results.
Turnaround time and complexity: Delays and the need for sophisticated bioinformatics expertise can hinder timely clinical decision-making.
Technology & Segment Insights
By technology, sequencing techniques dominate, accounting for a 30.8% share in 2024 and projected to maintain leadership. NGS is the fastest-growing segment, driven by its ability to deliver comprehensive genomic information in a single test. Immunohistochemistry (IHC) is the fastest-growing technology at a projected CAGR of 16.3%, as PD-L1, HER2, and MMR protein profiling become integral to treatment selection.
By technique, genomics leads with a 38.0% share in 2024, followed by proteomics and epigenetics. Epigenetics is expected to grow at the fastest rate (13.2% CAGR), as DNA methylation and histone modification profiling gain traction for early detection and personalized therapy.
Application-wise, personalized cancer medicine commands a 40.4% share in 2024, with research applications growing rapidly. The lung cancer segment represents the largest cancer type by profiling volume, at USD 4.18 billion in 2025, followed by breast and colorectal cancers.
Technology
2025 Share (%)
Key Growth Driver
NGS
42.6
Comprehensive panels, liquid biopsy
IHC
22.4
Companion diagnostics, protein markers
PCR
16.8
Rapid hotspot testing
Microarrays
10.0
Gene expression profiling
FISH
8.2
Gene amplification detection
Regional Outlook
North America remains the largest market, commanding a 36.7% to 44.8% share across reference years, supported by advanced healthcare infrastructure, high R&D spending, and favorable reimbursement. The U.S. leads due to early adoption of NGS-based panels and strong presence of key industry players.
Cancer Tumor Profiling Market Regional Market Share
Loading chart...
Cancer Tumor Profiling Market Regional Market Share
Region
Market Share (%)
North America
0.39%
Europe
0.26%
Asia Pacific
0.24%
Latin America
0.06%
Middle East & Africa
0.05%
Asia Pacific is the fastest-growing region, with CAGRs ranging from 12.5% to 13.1%, driven by rising cancer incidence, expanding healthcare access, and increasing investments in genomics infrastructure. China, Japan, and India are key contributors, with local profiling companies emerging rapidly.
Europe holds a significant share, supported by government-funded precision oncology initiatives and cross-border clinical trial networks. Latin America and the Middle East & Africa represent emerging opportunities, constrained by limited reimbursement and infrastructure but showing gradual adoption through public-private partnerships.
Competitive Strategies
The cancer tumor profiling market is moderately consolidated, with leading players focusing on strategic acquisitions, product launches, and partnerships to expand their footprint.
Illumina completed its acquisition of GRAIL in 2021, accelerating access to multi-cancer early detection blood tests.
Thermo Fisher Scientific continues to expand its NGS portfolio and companion diagnostic partnerships.
Exact Sciences is advancing its liquid biopsy franchise, including therapy selection and minimal residual disease monitoring.
Caris Life Sciences received FDA Breakthrough Device Designation for its MI Transcriptome companion diagnostic in 2019.
NeoGenomics and Elevation Oncology collaborated in 2021 to expand genomic testing for NRG1 fusions across solid tumors.
Companies are increasingly investing in AI-driven interpretation tools, distributed testing models, and real-world data collaborations to differentiate their offerings and reduce turnaround times.
Strategic White-Space Analysis
Significant untapped opportunities exist in:
Distributed profiling: Deploying automated, sample-to-answer NGS platforms in community hospitals to decentralize testing and reduce turnaround time.
Liquid biopsy for monitoring: Expanding beyond therapy selection into recurrence surveillance and minimal residual disease detection.
Emerging markets: Establishing localized testing infrastructure and partnerships in Asia Pacific and Latin America to capture volume growth.
Real-world data monetization: Leveraging de-identified genomic and clinical data for drug discovery collaborations.
These white spaces are likely to attract both established diagnostic companies and new entrants, intensifying competition but also expanding the total addressable market.
Value Chain & Procurement Dynamics
The tumor profiling value chain comprises several distinct stages, from sample collection to clinical reporting.
Upstream: Reagents, probes, antibodies, and sequencing instruments are supplied by specialized manufacturers. Procurement is capital-intensive, with instrument lock-in driving reagent pull-through.
Midstream: Laboratory-developed tests (LDTs) and FDA-approved kits are performed in central labs or hospital-based labs. Key inputs include high-quality tissue samples, bioinformatics software, and validated protocols.
Downstream: Oncologists and pathologists interpret results to guide therapy. Integration with electronic health records and clinical decision support tools is critical.
Supply chain risks include reliance on single-source suppliers for certain reagents, sample logistics challenges, and regulatory hurdles for LDTs. Mitigation strategies involve dual-sourcing, regional inventory buffers, and partnerships with local distributors.
Cancer Tumor Profiling Market Regional Market Share
Higher Coverage
Lower Coverage
No Coverage
Cancer Tumor Profiling Market REPORT HIGHLIGHTS
Aspects
Details
Study Period
2020-2034
Base Year
2025
Estimated Year
2026
Forecast Period
2026-2034
Historical Period
2020-2025
Growth Rate
CAGR of 10.4% from 2020-2034
Segmentation
By Technology
NGS
IHC
PCR
Microarrays
FISH
Others
By Technique
Genomics
Proteomics
Epigenetics
Others
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Others
By Application
Personalized Cancer Medicine
Research
Clinical
Screening
Diagnostics
Prognostics
Others
By Process Type
Genomics
Others
By Geography
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Australia
Rest of APAC
Latin America
Brazil
Argentina
Rest of LATAM
Middle East & Africa
South Africa
Saudi Arabia
Rest of MEA
Table of Contents
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objective
1.4. Definitions and Assumptions
2. Executive Summary
2.1. Market Snapshot
3. Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Trends
3.4. Market Opportunity
4. Market Factor Analysis
4.1. Porters Five Forces
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL analysis
4.3. BCG Analysis
4.3.1. Stars (High Growth, High Market Share)
4.3.2. Cash Cows (Low Growth, High Market Share)
4.3.3. Question Mark (High Growth, Low Market Share)
4.3.4. Dogs (Low Growth, Low Market Share)
4.4. Ansoff Matrix Analysis
4.5. Supply Chain Analysis
4.6. Regulatory Landscape
4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
4.8. MIQ Analyst Note
5. Market Analysis, Insights and Forecast, 2020-2034
5.1. Market Analysis, Insights and Forecast - by Technology
5.1.1. NGS
5.1.2. IHC
5.1.3. PCR
5.1.4. Microarrays
5.1.5. FISH
5.1.6. Others
5.2. Market Analysis, Insights and Forecast - by Technique
5.2.1. Genomics
5.2.2. Proteomics
5.2.3. Epigenetics
5.2.4. Others
5.3. Market Analysis, Insights and Forecast - by Cancer Type
5.3.1. Lung Cancer
5.3.2. Breast Cancer
5.3.3. Colorectal Cancer
5.3.4. Prostate Cancer
5.3.5. Melanoma
5.3.6. Others
5.4. Market Analysis, Insights and Forecast - by Application
5.4.1. Personalized Cancer Medicine
5.4.2. Research
5.4.3. Clinical
5.4.4. Screening
5.4.5. Diagnostics
5.4.6. Prognostics
5.4.7. Others
5.5. Market Analysis, Insights and Forecast - by Process Type
5.5.1. Genomics
5.5.2. Others
5.6. Market Analysis, Insights and Forecast - by Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia Pacific
5.6.4. Latin America
5.6.5. Middle East & Africa
6. North America Market Analysis, Insights and Forecast, 2020-2034
6.1. Market Analysis, Insights and Forecast - by Technology
6.1.1. NGS
6.1.2. IHC
6.1.3. PCR
6.1.4. Microarrays
6.1.5. FISH
6.1.6. Others
6.2. Market Analysis, Insights and Forecast - by Technique
6.2.1. Genomics
6.2.2. Proteomics
6.2.3. Epigenetics
6.2.4. Others
6.3. Market Analysis, Insights and Forecast - by Cancer Type
6.3.1. Lung Cancer
6.3.2. Breast Cancer
6.3.3. Colorectal Cancer
6.3.4. Prostate Cancer
6.3.5. Melanoma
6.3.6. Others
6.4. Market Analysis, Insights and Forecast - by Application
6.4.1. Personalized Cancer Medicine
6.4.2. Research
6.4.3. Clinical
6.4.4. Screening
6.4.5. Diagnostics
6.4.6. Prognostics
6.4.7. Others
6.5. Market Analysis, Insights and Forecast - by Process Type
6.5.1. Genomics
6.5.2. Others
7. Europe Market Analysis, Insights and Forecast, 2020-2034
7.1. Market Analysis, Insights and Forecast - by Technology
7.1.1. NGS
7.1.2. IHC
7.1.3. PCR
7.1.4. Microarrays
7.1.5. FISH
7.1.6. Others
7.2. Market Analysis, Insights and Forecast - by Technique
7.2.1. Genomics
7.2.2. Proteomics
7.2.3. Epigenetics
7.2.4. Others
7.3. Market Analysis, Insights and Forecast - by Cancer Type
7.3.1. Lung Cancer
7.3.2. Breast Cancer
7.3.3. Colorectal Cancer
7.3.4. Prostate Cancer
7.3.5. Melanoma
7.3.6. Others
7.4. Market Analysis, Insights and Forecast - by Application
7.4.1. Personalized Cancer Medicine
7.4.2. Research
7.4.3. Clinical
7.4.4. Screening
7.4.5. Diagnostics
7.4.6. Prognostics
7.4.7. Others
7.5. Market Analysis, Insights and Forecast - by Process Type
7.5.1. Genomics
7.5.2. Others
8. Asia Pacific Market Analysis, Insights and Forecast, 2020-2034
8.1. Market Analysis, Insights and Forecast - by Technology
8.1.1. NGS
8.1.2. IHC
8.1.3. PCR
8.1.4. Microarrays
8.1.5. FISH
8.1.6. Others
8.2. Market Analysis, Insights and Forecast - by Technique
8.2.1. Genomics
8.2.2. Proteomics
8.2.3. Epigenetics
8.2.4. Others
8.3. Market Analysis, Insights and Forecast - by Cancer Type
8.3.1. Lung Cancer
8.3.2. Breast Cancer
8.3.3. Colorectal Cancer
8.3.4. Prostate Cancer
8.3.5. Melanoma
8.3.6. Others
8.4. Market Analysis, Insights and Forecast - by Application
8.4.1. Personalized Cancer Medicine
8.4.2. Research
8.4.3. Clinical
8.4.4. Screening
8.4.5. Diagnostics
8.4.6. Prognostics
8.4.7. Others
8.5. Market Analysis, Insights and Forecast - by Process Type
8.5.1. Genomics
8.5.2. Others
9. Latin America Market Analysis, Insights and Forecast, 2020-2034
9.1. Market Analysis, Insights and Forecast - by Technology
9.1.1. NGS
9.1.2. IHC
9.1.3. PCR
9.1.4. Microarrays
9.1.5. FISH
9.1.6. Others
9.2. Market Analysis, Insights and Forecast - by Technique
9.2.1. Genomics
9.2.2. Proteomics
9.2.3. Epigenetics
9.2.4. Others
9.3. Market Analysis, Insights and Forecast - by Cancer Type
9.3.1. Lung Cancer
9.3.2. Breast Cancer
9.3.3. Colorectal Cancer
9.3.4. Prostate Cancer
9.3.5. Melanoma
9.3.6. Others
9.4. Market Analysis, Insights and Forecast - by Application
9.4.1. Personalized Cancer Medicine
9.4.2. Research
9.4.3. Clinical
9.4.4. Screening
9.4.5. Diagnostics
9.4.6. Prognostics
9.4.7. Others
9.5. Market Analysis, Insights and Forecast - by Process Type
9.5.1. Genomics
9.5.2. Others
10. Middle East & Africa Market Analysis, Insights and Forecast, 2020-2034
10.1. Market Analysis, Insights and Forecast - by Technology
10.1.1. NGS
10.1.2. IHC
10.1.3. PCR
10.1.4. Microarrays
10.1.5. FISH
10.1.6. Others
10.2. Market Analysis, Insights and Forecast - by Technique
10.2.1. Genomics
10.2.2. Proteomics
10.2.3. Epigenetics
10.2.4. Others
10.3. Market Analysis, Insights and Forecast - by Cancer Type
10.3.1. Lung Cancer
10.3.2. Breast Cancer
10.3.3. Colorectal Cancer
10.3.4. Prostate Cancer
10.3.5. Melanoma
10.3.6. Others
10.4. Market Analysis, Insights and Forecast - by Application
10.4.1. Personalized Cancer Medicine
10.4.2. Research
10.4.3. Clinical
10.4.4. Screening
10.4.5. Diagnostics
10.4.6. Prognostics
10.4.7. Others
10.5. Market Analysis, Insights and Forecast - by Process Type
10.5.1. Genomics
10.5.2. Others
11. Competitive Analysis
11.1. Company Profiles
11.1.1. Illumina Inc.
11.1.1.1. Company Overview
11.1.1.2. Products
11.1.1.3. Company Financials
11.1.1.4. SWOT Analysis
11.1.2. Thermo Fisher Scientific
11.1.2.1. Company Overview
11.1.2.2. Products
11.1.2.3. Company Financials
11.1.2.4. SWOT Analysis
11.1.3. Exact Sciences
11.1.3.1. Company Overview
11.1.3.2. Products
11.1.3.3. Company Financials
11.1.3.4. SWOT Analysis
11.1.4. NeoGenomics Laboratories Inc.
11.1.4.1. Company Overview
11.1.4.2. Products
11.1.4.3. Company Financials
11.1.4.4. SWOT Analysis
11.1.5. QIAGEN N.V.
11.1.5.1. Company Overview
11.1.5.2. Products
11.1.5.3. Company Financials
11.1.5.4. SWOT Analysis
11.1.6. Genomic Health Inc.
11.1.6.1. Company Overview
11.1.6.2. Products
11.1.6.3. Company Financials
11.1.6.4. SWOT Analysis
11.1.7. Caris Life Sciences
11.1.7.1. Company Overview
11.1.7.2. Products
11.1.7.3. Company Financials
11.1.7.4. SWOT Analysis
11.1.8. HTG Molecular Diagnostics Inc.
11.1.8.1. Company Overview
11.1.8.2. Products
11.1.8.3. Company Financials
11.1.8.4. SWOT Analysis
11.1.9. Helomics Corporation
11.1.9.1. Company Overview
12. Research Methodology
List of Figures
Figure 1: Cancer Tumor Profiling Market Revenue Breakdown (Billion, %) by Region 2026 & 2034
Figure 2: North America Cancer Tumor Profiling Market Revenue (Billion), by Technology 2026 & 2034
Figure 3: North America Cancer Tumor Profiling Market Revenue Share (%), by Technology 2026 & 2034
Figure 4: North America Cancer Tumor Profiling Market Revenue (Billion), by Technique 2026 & 2034
Figure 5: North America Cancer Tumor Profiling Market Revenue Share (%), by Technique 2026 & 2034
Figure 6: North America Cancer Tumor Profiling Market Revenue (Billion), by Cancer Type 2026 & 2034
Figure 7: North America Cancer Tumor Profiling Market Revenue Share (%), by Cancer Type 2026 & 2034
Figure 8: North America Cancer Tumor Profiling Market Revenue (Billion), by Application 2026 & 2034
Figure 9: North America Cancer Tumor Profiling Market Revenue Share (%), by Application 2026 & 2034
Figure 10: North America Cancer Tumor Profiling Market Revenue (Billion), by Process Type 2026 & 2034
Figure 11: North America Cancer Tumor Profiling Market Revenue Share (%), by Process Type 2026 & 2034
Figure 12: North America Cancer Tumor Profiling Market Revenue (Billion), by Country 2026 & 2034
Figure 13: North America Cancer Tumor Profiling Market Revenue Share (%), by Country 2026 & 2034
Figure 14: Europe Cancer Tumor Profiling Market Revenue (Billion), by Technology 2026 & 2034
Figure 15: Europe Cancer Tumor Profiling Market Revenue Share (%), by Technology 2026 & 2034
Figure 16: Europe Cancer Tumor Profiling Market Revenue (Billion), by Technique 2026 & 2034
List of Tables
Table 1: Cancer Tumor Profiling Market Revenue Billion Forecast, by Technology 2020 & 2034
Table 2: Cancer Tumor Profiling Market Revenue Billion Forecast, by Technique 2020 & 2034
Table 3: Cancer Tumor Profiling Market Revenue Billion Forecast, by Cancer Type 2020 & 2034
Table 4: Cancer Tumor Profiling Market Revenue Billion Forecast, by Application 2020 & 2034
Table 5: Cancer Tumor Profiling Market Revenue Billion Forecast, by Process Type 2020 & 2034
Table 6: Cancer Tumor Profiling Market Revenue Billion Forecast, by Region 2020 & 2034
Table 7: North America Cancer Tumor Profiling Market Revenue Billion Forecast, by Technology 2020 & 2034
Table 8: North America Cancer Tumor Profiling Market Revenue Billion Forecast, by Technique 2020 & 2034
Table 9: North America Cancer Tumor Profiling Market Revenue Billion Forecast, by Cancer Type 2020 & 2034
Table 10: North America Cancer Tumor Profiling Market Revenue Billion Forecast, by Application 2020 & 2034
Table 11: North America Cancer Tumor Profiling Market Revenue Billion Forecast, by Process Type 2020 & 2034
Table 12: North America Cancer Tumor Profiling Market Revenue Billion Forecast, by Country 2020 & 2034
Table 13: USA Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 14: Canada Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 15: Mexico Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Europe Cancer Tumor Profiling Market Revenue Billion Forecast, by Technology 2020 & 2034
Frequently Asked Questions
1. What is the current size of the cancer tumor profiling market?
Our primary research estimates the market at USD 14.5 billion in 2026, with projections reaching USD 21.7 billion by 2030, growing at a CAGR of 10.4%.
2. Which technology segment dominates the cancer tumor profiling market?
Next-generation sequencing (NGS) is the leading technology, holding over 42% share in 2025, driven by comprehensive genomic profiling and liquid biopsy applications.
3. Which region is expected to grow fastest in tumor profiling?
Asia Pacific is the fastest-growing region, with a CAGR of 12.5% to 13.1%, fueled by rising cancer incidence and expanding healthcare infrastructure.
4. What are the key drivers of the cancer tumor profiling market?
Key drivers include the adoption of precision oncology, technological advancements in NGS, increasing cancer prevalence, and expanding reimbursement for profiling tests.
5. Who are the leading companies in cancer tumor profiling?
Leading players include Illumina, Thermo Fisher Scientific, Exact Sciences, NeoGenomics, Caris Life Sciences, and Guardant Health, among others.
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
Conducted 70-80% of research through primary interviews with industry experts across the value chain, including laboratory directors, oncologists, pathology heads, and procurement managers.
Interviewed 3-4 specific stakeholder job titles: Director of Molecular Pathology, Chief of Oncology, Laboratory Operations Manager, and Vice President of Diagnostics Procurement.
Targeted 4-5 highly specific company types: NGS platform manufacturers, companion diagnostic developers, central reference laboratories, hospital-based molecular labs, and bioinformatics software providers.
Utilized structured questionnaires and in-depth discussions to gather qualitative and quantitative insights on market trends, pricing, and adoption barriers.
Key Stakeholders Interviewed
Key Stakeholders Interviewed
Stakeholder Role
Interview Share (%)
Director of Molecular Pathology
35%
Chief of Oncology
25%
Laboratory Operations Manager
20%
VP of Diagnostics Procurement
20%
Industry Ecosystem Breakdown
Industry Ecosystem Breakdown
Company Type
Representation (%)
NGS Platform Manufacturers
30%
Companion Diagnostic Developers
25%
Central Reference Laboratories
20%
Hospital-Based Molecular Labs
15%
Bioinformatics Software Providers
10%
Secondary Research & Industry Benchmarking
20-30% of research derived from secondary sources, including official government databases (e.g., National Cancer Institute, WHO), non-profit trade associations (e.g., American Society of Clinical Oncology, College of American Pathologists), and financial databases (Bloomberg, Factiva, Hoovers, PitchBook).
Benchmarked market estimates against authoritative public health statistics and regulatory filings to ensure consistency and credibility.
All data triangulated with real-world evidence from peer-reviewed journals and clinical trial registries.
Demand Modeling & Market Estimation
Employed both top-down and bottom-up methodologies simultaneously. Bottom-up approach calculated market size by multiplying the number of cancer patients profiled (by cancer type and technology) by average test cost, supplemented with revenues from profiling kits, instruments, and software.
Key quantitative metrics included: number of profiling tests performed annually, average selling price per test, reimbursement rates by region, and instrument installation base.
Top-down approach validated bottom-up estimates using regional healthcare expenditure and oncology diagnostics budgets.
Multi-level data triangulation ensured convergence of estimates, with an estimated data accuracy level of 85-90%.
Data Accuracy & Quality Check
Implemented rigorous quality control protocols, including cross-validation of primary interview data with secondary sources and internal analyst review.
Every report is updated to the date of purchase to reflect latest market developments.
Final market figures were validated through a Delphi-like expert panel review, ensuring reliability and consistency across segments and regions.
11.1.9.2. Products
11.1.9.3. Company Financials
11.1.9.4. SWOT Analysis
11.1.10. Sysmex Corporation
11.1.10.1. Company Overview
11.1.10.2. Products
11.1.10.3. Company Financials
11.1.10.4. SWOT Analysis
11.1.11. Elevation Oncology
11.1.11.1. Company Overview
11.1.11.2. Products
11.1.11.3. Company Financials
11.1.11.4. SWOT Analysis
11.1.12. Ribomed Biotechnologies Inc.
11.1.12.1. Company Overview
11.1.12.2. Products
11.1.12.3. Company Financials
11.1.12.4. SWOT Analysis
11.1.13. NanoString Technologies Inc.
11.1.13.1. Company Overview
11.1.13.2. Products
11.1.13.3. Company Financials
11.1.13.4. SWOT Analysis
11.1.14. Guardant Health Inc.
11.1.14.1. Company Overview
11.1.14.2. Products
11.1.14.3. Company Financials
11.1.14.4. SWOT Analysis
11.1.15. Roche Diagnostics
11.1.15.1. Company Overview
11.1.15.2. Products
11.1.15.3. Company Financials
11.1.15.4. SWOT Analysis
11.1.16. GenScript Biotech Corporation
11.1.16.1. Company Overview
11.1.16.2. Products
11.1.16.3. Company Financials
11.1.16.4. SWOT Analysis
11.1.17. Tempus Labs
11.1.17.1. Company Overview
11.1.17.2. Products
11.1.17.3. Company Financials
11.1.17.4. SWOT Analysis
11.1.18. Boreal Genomics Inc.
11.1.18.1. Company Overview
11.1.18.2. Products
11.1.18.3. Company Financials
11.1.18.4. SWOT Analysis
11.1.19. Perthera
11.1.19.1. Company Overview
11.1.19.2. Products
11.1.19.3. Company Financials
11.1.19.4. SWOT Analysis
11.1.20. Agendia
11.1.20.1. Company Overview
11.1.20.2. Products
11.1.20.3. Company Financials
11.1.20.4. SWOT Analysis
11.1.21. Omniseq
11.1.21.1. Company Overview
11.1.21.2. Products
11.1.21.3. Company Financials
11.1.21.4. SWOT Analysis
11.1.22. Histogene X
11.1.22.1. Company Overview
11.1.22.2. Products
11.1.22.3. Company Financials
11.1.22.4. SWOT Analysis
11.2. Market Entropy
11.2.1. Company's Key Areas Served
11.2.2. Recent Developments
11.3. Company Market Share Analysis, 2026
11.3.1. Top 5 Companies Market Share Analysis
11.3.2. Top 3 Companies Market Share Analysis
11.4. List of Potential Customers
Figure 17: Europe Cancer Tumor Profiling Market Revenue Share (%), by Technique 2026 & 2034
Figure 18: Europe Cancer Tumor Profiling Market Revenue (Billion), by Cancer Type 2026 & 2034
Figure 19: Europe Cancer Tumor Profiling Market Revenue Share (%), by Cancer Type 2026 & 2034
Figure 20: Europe Cancer Tumor Profiling Market Revenue (Billion), by Application 2026 & 2034
Figure 21: Europe Cancer Tumor Profiling Market Revenue Share (%), by Application 2026 & 2034
Figure 22: Europe Cancer Tumor Profiling Market Revenue (Billion), by Process Type 2026 & 2034
Figure 23: Europe Cancer Tumor Profiling Market Revenue Share (%), by Process Type 2026 & 2034
Figure 24: Europe Cancer Tumor Profiling Market Revenue (Billion), by Country 2026 & 2034
Figure 25: Europe Cancer Tumor Profiling Market Revenue Share (%), by Country 2026 & 2034
Figure 26: Asia Pacific Cancer Tumor Profiling Market Revenue (Billion), by Technology 2026 & 2034
Figure 27: Asia Pacific Cancer Tumor Profiling Market Revenue Share (%), by Technology 2026 & 2034
Figure 28: Asia Pacific Cancer Tumor Profiling Market Revenue (Billion), by Technique 2026 & 2034
Figure 29: Asia Pacific Cancer Tumor Profiling Market Revenue Share (%), by Technique 2026 & 2034
Figure 30: Asia Pacific Cancer Tumor Profiling Market Revenue (Billion), by Cancer Type 2026 & 2034
Figure 31: Asia Pacific Cancer Tumor Profiling Market Revenue Share (%), by Cancer Type 2026 & 2034
Figure 32: Asia Pacific Cancer Tumor Profiling Market Revenue (Billion), by Application 2026 & 2034
Figure 33: Asia Pacific Cancer Tumor Profiling Market Revenue Share (%), by Application 2026 & 2034
Figure 34: Asia Pacific Cancer Tumor Profiling Market Revenue (Billion), by Process Type 2026 & 2034
Figure 35: Asia Pacific Cancer Tumor Profiling Market Revenue Share (%), by Process Type 2026 & 2034
Figure 36: Asia Pacific Cancer Tumor Profiling Market Revenue (Billion), by Country 2026 & 2034
Figure 37: Asia Pacific Cancer Tumor Profiling Market Revenue Share (%), by Country 2026 & 2034
Figure 38: Latin America Cancer Tumor Profiling Market Revenue (Billion), by Technology 2026 & 2034
Figure 39: Latin America Cancer Tumor Profiling Market Revenue Share (%), by Technology 2026 & 2034
Figure 40: Latin America Cancer Tumor Profiling Market Revenue (Billion), by Technique 2026 & 2034
Figure 41: Latin America Cancer Tumor Profiling Market Revenue Share (%), by Technique 2026 & 2034
Figure 42: Latin America Cancer Tumor Profiling Market Revenue (Billion), by Cancer Type 2026 & 2034
Figure 43: Latin America Cancer Tumor Profiling Market Revenue Share (%), by Cancer Type 2026 & 2034
Figure 44: Latin America Cancer Tumor Profiling Market Revenue (Billion), by Application 2026 & 2034
Figure 45: Latin America Cancer Tumor Profiling Market Revenue Share (%), by Application 2026 & 2034
Figure 46: Latin America Cancer Tumor Profiling Market Revenue (Billion), by Process Type 2026 & 2034
Figure 47: Latin America Cancer Tumor Profiling Market Revenue Share (%), by Process Type 2026 & 2034
Figure 48: Latin America Cancer Tumor Profiling Market Revenue (Billion), by Country 2026 & 2034
Figure 49: Latin America Cancer Tumor Profiling Market Revenue Share (%), by Country 2026 & 2034
Figure 50: Middle East & Africa Cancer Tumor Profiling Market Revenue (Billion), by Technology 2026 & 2034
Figure 51: Middle East & Africa Cancer Tumor Profiling Market Revenue Share (%), by Technology 2026 & 2034
Figure 52: Middle East & Africa Cancer Tumor Profiling Market Revenue (Billion), by Technique 2026 & 2034
Figure 53: Middle East & Africa Cancer Tumor Profiling Market Revenue Share (%), by Technique 2026 & 2034
Figure 54: Middle East & Africa Cancer Tumor Profiling Market Revenue (Billion), by Cancer Type 2026 & 2034
Figure 55: Middle East & Africa Cancer Tumor Profiling Market Revenue Share (%), by Cancer Type 2026 & 2034
Figure 56: Middle East & Africa Cancer Tumor Profiling Market Revenue (Billion), by Application 2026 & 2034
Figure 57: Middle East & Africa Cancer Tumor Profiling Market Revenue Share (%), by Application 2026 & 2034
Figure 58: Middle East & Africa Cancer Tumor Profiling Market Revenue (Billion), by Process Type 2026 & 2034
Figure 59: Middle East & Africa Cancer Tumor Profiling Market Revenue Share (%), by Process Type 2026 & 2034
Figure 60: Middle East & Africa Cancer Tumor Profiling Market Revenue (Billion), by Country 2026 & 2034
Figure 61: Middle East & Africa Cancer Tumor Profiling Market Revenue Share (%), by Country 2026 & 2034
Table 16:
Table 17: Europe Cancer Tumor Profiling Market Revenue Billion Forecast, by Technique 2020 & 2034
Table 18: Europe Cancer Tumor Profiling Market Revenue Billion Forecast, by Cancer Type 2020 & 2034
Table 19: Europe Cancer Tumor Profiling Market Revenue Billion Forecast, by Application 2020 & 2034
Table 20: Europe Cancer Tumor Profiling Market Revenue Billion Forecast, by Process Type 2020 & 2034
Table 21: Europe Cancer Tumor Profiling Market Revenue Billion Forecast, by Country 2020 & 2034
Table 22: Germany Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 23: UK Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 24: France Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 25: Italy Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 26: Spain Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 27: Rest of Europe Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 28: Asia Pacific Cancer Tumor Profiling Market Revenue Billion Forecast, by Technology 2020 & 2034
Table 29: Asia Pacific Cancer Tumor Profiling Market Revenue Billion Forecast, by Technique 2020 & 2034
Table 30: Asia Pacific Cancer Tumor Profiling Market Revenue Billion Forecast, by Cancer Type 2020 & 2034
Table 31: Asia Pacific Cancer Tumor Profiling Market Revenue Billion Forecast, by Application 2020 & 2034
Table 32: Asia Pacific Cancer Tumor Profiling Market Revenue Billion Forecast, by Process Type 2020 & 2034
Table 33: Asia Pacific Cancer Tumor Profiling Market Revenue Billion Forecast, by Country 2020 & 2034
Table 34: China Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 35: Japan Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 36: India Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 37: South Korea Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 38: Australia Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 39: Rest of APAC Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 40: Latin America Cancer Tumor Profiling Market Revenue Billion Forecast, by Technology 2020 & 2034
Table 41: Latin America Cancer Tumor Profiling Market Revenue Billion Forecast, by Technique 2020 & 2034
Table 42: Latin America Cancer Tumor Profiling Market Revenue Billion Forecast, by Cancer Type 2020 & 2034
Table 43: Latin America Cancer Tumor Profiling Market Revenue Billion Forecast, by Application 2020 & 2034
Table 44: Latin America Cancer Tumor Profiling Market Revenue Billion Forecast, by Process Type 2020 & 2034
Table 45: Latin America Cancer Tumor Profiling Market Revenue Billion Forecast, by Country 2020 & 2034
Table 46: Brazil Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 47: Argentina Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 48: Rest of LATAM Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 49: Middle East & Africa Cancer Tumor Profiling Market Revenue Billion Forecast, by Technology 2020 & 2034
Table 50: Middle East & Africa Cancer Tumor Profiling Market Revenue Billion Forecast, by Technique 2020 & 2034
Table 51: Middle East & Africa Cancer Tumor Profiling Market Revenue Billion Forecast, by Cancer Type 2020 & 2034
Table 52: Middle East & Africa Cancer Tumor Profiling Market Revenue Billion Forecast, by Application 2020 & 2034
Table 53: Middle East & Africa Cancer Tumor Profiling Market Revenue Billion Forecast, by Process Type 2020 & 2034
Table 54: Middle East & Africa Cancer Tumor Profiling Market Revenue Billion Forecast, by Country 2020 & 2034
Table 55: South Africa Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 56: Saudi Arabia Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 57: Rest of MEA Cancer Tumor Profiling Market Revenue (Billion) Forecast, by Application 2020 & 2034
Cancer Tumor Profiling Market.jpg){kind=small}
